CN115209955A - 治疗家族性自主神经功能障碍的化合物 - Google Patents

治疗家族性自主神经功能障碍的化合物 Download PDF

Info

Publication number
CN115209955A
CN115209955A CN202080096472.5A CN202080096472A CN115209955A CN 115209955 A CN115209955 A CN 115209955A CN 202080096472 A CN202080096472 A CN 202080096472A CN 115209955 A CN115209955 A CN 115209955A
Authority
CN
China
Prior art keywords
methyl
pyrimidin
chloro
amine
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096472.5A
Other languages
English (en)
Chinese (zh)
Inventor
张南京
M·A·阿诺德
A·达卡
G·M·卡普
T·T·梁
C·莫里尔
J·纳拉辛汉
N·A·纳雷什金
A·图尔波夫
J·王
张小燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN115209955A publication Critical patent/CN115209955A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
CN202080096472.5A 2019-12-12 2020-12-07 治疗家族性自主神经功能障碍的化合物 Pending CN115209955A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
US62/947,049 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
CN115209955A true CN115209955A (zh) 2022-10-18

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096472.5A Pending CN115209955A (zh) 2019-12-12 2020-12-07 治疗家族性自主神经功能障碍的化合物

Country Status (14)

Country Link
US (1) US20230057568A1 (https=)
EP (1) EP4072677A1 (https=)
JP (2) JP2023506488A (https=)
KR (1) KR20220113700A (https=)
CN (1) CN115209955A (https=)
AU (1) AU2020402717A1 (https=)
BR (1) BR112022011364A2 (https=)
CA (1) CA3160053A1 (https=)
CL (1) CL2022001523A1 (https=)
CO (1) CO2022008195A2 (https=)
IL (1) IL293764A (https=)
MX (1) MX2022007094A (https=)
PE (1) PE20221581A1 (https=)
WO (1) WO2021118929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MX2024002887A (es) * 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
CN103242341A (zh) * 2013-04-19 2013-08-14 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
US20130317045A1 (en) * 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2016115434A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
WO2018134685A2 (en) * 2017-01-17 2018-07-26 Liverpool School Of Tropical Medicine Compounds
CN110312528A (zh) * 2017-02-20 2019-10-08 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
US20130317045A1 (en) * 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341A (zh) * 2013-04-19 2013-08-14 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
WO2016115434A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
WO2018134685A2 (en) * 2017-01-17 2018-07-26 Liverpool School Of Tropical Medicine Compounds
CN110312528A (zh) * 2017-02-20 2019-10-08 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLUMBUS, OHIO, US REGISTRY[ONLINE]: "STN检索报告", 《STN REGISTRY》, 6 December 2011 (2011-12-06), pages 1 *
TERRY PANCHAL ET AL.: "Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)", 《BIOORG. MED. CHEM. LETT.》, vol. 19, pages 6815 *
熊淑华等: "自身免疫性自主神经节病的诊治新进展", 《中国临床神经科学》, vol. 20, no. 06, pages 690 - 693 *

Also Published As

Publication number Publication date
AU2020402717A1 (en) 2022-06-23
BR112022011364A2 (pt) 2022-08-23
WO2021118929A1 (en) 2021-06-17
KR20220113700A (ko) 2022-08-16
JP2025133750A (ja) 2025-09-11
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
JP2023506488A (ja) 2023-02-16
CA3160053A1 (en) 2021-06-17
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
IL293764A (en) 2022-08-01
EP4072677A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
CN113795304A (zh) 用于治疗家族性自主神经功能障碍的噻吩并[3,2-b]吡啶-7-胺化合物
JP7720864B2 (ja) ハンチントン病を処置するためのｈｔｔモジュレータ
CN104583196B (zh) 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN119997954A (zh) 用于治疗脊髓小脑性共济失调3型的化合物
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
TW201734020A (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
JP2022078137A (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
EA024201B1 (ru) Ингибиторы вируса гепатита с
CN115209955A (zh) 治疗家族性自主神经功能障碍的化合物
TW202400606A (zh) 中環或大環之經苄基取代之雜環衍生物及相關用途
CN116969920A (zh) 稠合哒嗪衍生物及其制备方法与医药用途
CN108884093A (zh) 6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂*多巴胺D3配体
EP2370442B1 (en) 3-Aminocyclopentanecarboxamides as chemokine receptor modulators
KR20190133703A (ko) 이속사졸 카르복사미드 화합물 및 이의 용도
JP7634532B2 (ja) 寄生虫病の処置のための化合物及び組成物
JP2024540477A (ja) ハンチントン病を治療するためのｈｔｔモジュレータとしてのｎ－（２ｈ－インダゾール－５－イル）ピラジン－２－カルボキサミド誘導体及び類似化合物
HK40065747A (zh) 用於治疗家族性自主神经功能障碍的噻吩并[3，2-b]吡啶-7-胺化合物
AU2024332695A1 (en) Pyrazolyl compounds as emopamil binding protein inhibitors
KR20260061216A (ko) 에모파밀 결합 단백질 억제제로서의 피라졸릴 화합물
CN115003671A (zh) Jnk抑制剂、其药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination